Irem Hacisalihoglu Aydin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irem Hacisalihoglu Aydin has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Cana Aksoy Poyraz
Department of Psychiatry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
3 shared publications - Burç Çağrı Poyraz
Department of Psychiatry, Cerrahpasa Faculty of Medicine, Istanbul University–Cerrahpasa, Istanbul, Turkey [ protected
2 shared publications - Elif Burcu Ersungur Çelik
Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine
2 shared publications - Rif S. El-Mallakh
University of Louisville School of Medicine
2 shared publications - Ömer Faruk Demirel
Department of Psychiatry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkiye
2 shared publications Aishatu Salifu
University of Louisville, School of Medicine, Louisville, KY, USA
1 shared publication
Latest Publications
- 24 January 2026
- Published by S. Karger AG in Breast Care
- p. 1-9
Mastalgia, Radiological Yield, and Psychological Burden: A Cross-Sectional Comparative Study
Introduction: The aim of this study was to investigate the clinical, radiological, and psychological correlates of mastalgia and to determine the factors independently associated with anxiety and depression in women presenting with breast pain. Methods: In this cross-sectional study, 151 women with mastalgia and 69 controls undergoing breast imaging were assessed. Sociodemographic variables, pain characteristics, clinical history, visual analog scale (VAS) scores, and Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) scores were collected. Radiological evaluation was performed using ultrasound or mammography based on age, and magnetic resonance imaging findings were included when available. Group comparisons were performed statistically using univariate tests and multivariate linear regression was used to identify predictors of anxiety and depression among patients with mastalgia. Results: Women with mastalgia demonstrated significantly higher anxiety scores than controls (median BAI 10 vs. 7; p = 0.009), whereas depression scores did not differ. Among patients with mastalgia, noncyclic pain, palpable abnormalities, and a history of breast surgery were associated with greater anxiety according to univariate analysis. In the multivariate model, palpable breast stiffness (β = 5.30; p = 0.013) and a history of previous breast surgery (β = 8.67; p = 0.022) independently predicted increased anxiety, whereas cyclic pain was protective (β = −6.40; p = 0.007). Imaging yielded predominantly benign or normal findings, underscoring the low diagnostic contribution of routine radiological workup. Conclusion: Mastalgia is characterized by a substantial psychological burden despite a low prevalence of radiological abnormalities. Clinical features, such as palpable stiffness and a history of prior breast surgery, are more strongly linked to anxiety than the findings from imaging studies. These results support a more selective imaging strategy and highlight the importance of incorporating psychological assessment in the evaluation of breast pain.
- 24 January 2026
- Published by S. Karger AG in Breast Care
- p. 1-9
Mastalgia, Radiological Yield, and Psychological Burden: A Cross-Sectional Comparative Study
Introduction: The aim of this study was to investigate the clinical, radiological, and psychological correlates of mastalgia and to determine the factors independently associated with anxiety and depression in women presenting with breast pain. Methods: In this cross-sectional study, 151 women with mastalgia and 69 controls undergoing breast imaging were assessed. Sociodemographic variables, pain characteristics, clinical history, visual analog scale (VAS) scores, and Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) scores were collected. Radiological evaluation was performed using ultrasound or mammography based on age, and magnetic resonance imaging findings were included when available. Group comparisons were performed statistically using univariate tests and multivariate linear regression was used to identify predictors of anxiety and depression among patients with mastalgia. Results: Women with mastalgia demonstrated significantly higher anxiety scores than controls (median BAI 10 vs. 7; p = 0.009), whereas depression scores did not differ. Among patients with mastalgia, noncyclic pain, palpable abnormalities, and a history of breast surgery were associated with greater anxiety according to univariate analysis. In the multivariate model, palpable breast stiffness (β = 5.30; p = 0.013) and a history of previous breast surgery (β = 8.67; p = 0.022) independently predicted increased anxiety, whereas cyclic pain was protective (β = −6.40; p = 0.007). Imaging yielded predominantly benign or normal findings, underscoring the low diagnostic contribution of routine radiological workup. Conclusion: Mastalgia is characterized by a substantial psychological burden despite a low prevalence of radiological abnormalities. Clinical features, such as palpable stiffness and a history of prior breast surgery, are more strongly linked to anxiety than the findings from imaging studies. These results support a more selective imaging strategy and highlight the importance of incorporating psychological assessment in the evaluation of breast pain.
- Open Access
- 5 January 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (1) , 5
Indications for Dialysis in Lithium Toxicity: A Narrative Review
Lithium is the most reliable mood stabilizer available for the treatment of bipolar disorder. However, its use is limited by multiple concerns, including acute toxicity. Lithium levels have frequently been key to decisions regarding initiation of dialysis. Following the methodological principles of the Scale for the Assessment of Narrative Review Articles (SANRA), comprehensive searches were conducted across the following databases: PubMed, Embase, Web of Science, and Cochrane Library, without limitations on publication period. In an effort to standardize and objectify the decision to use dialysis, current treatment recommendations discuss clinical presentation but ultimately rely on measured serum lithium levels. Decision making can be improved if it takes into account whether lithium toxicity occurred slowly (which is equivalent to chronic toxicity, so that clinical signs of toxicity exceed expectations of measured lithium levels) or quickly (in which measured lithium levels exceed observed clinical severity). We propose that clinicians consider these factors and suggest that involving a broader interdisciplinary team, including psychiatry, in the decision-making process could enhance outcomes.
- 5 January 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (1) , 5
Open AccessIndications for Dialysis in Lithium Toxicity: A Narrative Review
Lithium is the most reliable mood stabilizer available for the treatment of bipolar disorder. However, its use is limited by multiple concerns, including acute toxicity. Lithium levels have frequently been key to decisions regarding initiation of dialysis. Following the methodological principles of the Scale for the Assessment of Narrative Review Articles (SANRA), comprehensive searches were conducted across the following databases: PubMed, Embase, Web of Science, and Cochrane Library, without limitations on publication period. In an effort to standardize and objectify the decision to use dialysis, current treatment recommendations discuss clinical presentation but ultimately rely on measured serum lithium levels. Decision making can be improved if it takes into account whether lithium toxicity occurred slowly (which is equivalent to chronic toxicity, so that clinical signs of toxicity exceed expectations of measured lithium levels) or quickly (in which measured lithium levels exceed observed clinical severity). We propose that clinicians consider these factors and suggest that involving a broader interdisciplinary team, including psychiatry, in the decision-making process could enhance outcomes.
- 6 October 2025
- Published by Taylor & Francis in Chronobiology International
- Vol. 42 (12) , 1679-1688
The impact of biological rhythms and sleep quality on the link between depression and functionality in bipolar disorder
This study examined the role of biological rhythms and sleep quality on the impact of depression on functionality in bipolar disorder (BD) and compared these factors between euthymic bipolar patients and healthy controls. Ninety-eight patients with BD were included in the study and recategorized as euthymic or depressive based on their Hamilton Depression Rating Scale scores, along with ninety-six healthy controls. Biological rhythms, functionality, and sleep quality were evaluated utilizing the Biological Rhythms Assessment in Neuropsychiatry, Functioning Assessment Short Test, and Pittsburgh Sleep Quality Index. Biological rhythms and sleep were more disrupted in bipolar depression, with no differences between euthymic patients and controls. Positive correlations were found among depression, functionality, sleep quality, and biological rhythms. Mediation analysis revealed that biological rhythm disturbances partially mediate the link between depression and functionality, while sleep quality does not. Interventions addressing both depression and biological rhythms may improve functionality in BD.
- 6 October 2025
- Published by Taylor & Francis in Chronobiology International
- Vol. 42 (12) , 1679-1688
The impact of biological rhythms and sleep quality on the link between depression and functionality in bipolar disorder
This study examined the role of biological rhythms and sleep quality on the impact of depression on functionality in bipolar disorder (BD) and compared these factors between euthymic bipolar patients and healthy controls. Ninety-eight patients with BD were included in the study and recategorized as euthymic or depressive based on their Hamilton Depression Rating Scale scores, along with ninety-six healthy controls. Biological rhythms, functionality, and sleep quality were evaluated utilizing the Biological Rhythms Assessment in Neuropsychiatry, Functioning Assessment Short Test, and Pittsburgh Sleep Quality Index. Biological rhythms and sleep were more disrupted in bipolar depression, with no differences between euthymic patients and controls. Positive correlations were found among depression, functionality, sleep quality, and biological rhythms. Mediation analysis revealed that biological rhythm disturbances partially mediate the link between depression and functionality, while sleep quality does not. Interventions addressing both depression and biological rhythms may improve functionality in BD.
- Open Access
- 30 June 2025
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 50 (2) , 328-340
Cognitive impairments, depression and quality of life 1 year after COVID-19 hospital discharge
Purpose: Following the acute stage of COVID-19, many patients have experienced persistent physical and neuropsychiatric symptoms, regardless of the severity of the illness. Key concerns like fatigue, depressive symptoms, and cognitive impairments have a detrimental effect on psychosocial functioning and quality of life. This study aims to explore cognitive impairments and depression one year after discharge from the hospital for COVID-19, along with implications for quality of life. Materials and Methods: Patients hospitalized with COVID-19 with mild-moderate disease severity were asked to participate in a 12-month follow-up evaluation. A total of 60 individuals who had recovered from COVID-19 were examined for cognitive functions, depressive symptoms, and quality of life. They were then compared to a healthy comparison group, matched for age and education, who had not been infected with COVID-19. Results: After 1 year following discharge, cognitive impairment was noted in 21.7% of COVID-19 patients, based on The Montreal Cognitive Assessment, while only 3.3% of the non-COVID-19 control group exhibited the same. Quality of life domains were largely comparable across groups. Depressive symptoms were identified as the main factor affecting quality of life domains in COVID-19 patients. Conclusion: Despite the potential for cognitive impairment to last for up to a year following hospital discharge, it does not seem to have a negative effect on the quality of life in our group of patients with mild-to-moderate disease severity. However, depressive symptoms were found to be the key indicators of quality of life.
- 30 June 2025
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 50 (2) , 328-340
Open AccessCognitive impairments, depression and quality of life 1 year after COVID-19 hospital discharge
Purpose: Following the acute stage of COVID-19, many patients have experienced persistent physical and neuropsychiatric symptoms, regardless of the severity of the illness. Key concerns like fatigue, depressive symptoms, and cognitive impairments have a detrimental effect on psychosocial functioning and quality of life. This study aims to explore cognitive impairments and depression one year after discharge from the hospital for COVID-19, along with implications for quality of life. Materials and Methods: Patients hospitalized with COVID-19 with mild-moderate disease severity were asked to participate in a 12-month follow-up evaluation. A total of 60 individuals who had recovered from COVID-19 were examined for cognitive functions, depressive symptoms, and quality of life. They were then compared to a healthy comparison group, matched for age and education, who had not been infected with COVID-19. Results: After 1 year following discharge, cognitive impairment was noted in 21.7% of COVID-19 patients, based on The Montreal Cognitive Assessment, while only 3.3% of the non-COVID-19 control group exhibited the same. Quality of life domains were largely comparable across groups. Depressive symptoms were identified as the main factor affecting quality of life domains in COVID-19 patients. Conclusion: Despite the potential for cognitive impairment to last for up to a year following hospital discharge, it does not seem to have a negative effect on the quality of life in our group of patients with mild-to-moderate disease severity. However, depressive symptoms were found to be the key indicators of quality of life.
- 25 June 2025
- Published by SAGE Publications in Annals of Clinical Psychiatry
- Vol. 36 (3) , 80-88
When an Antipsychotic Working as an Antidepressant, Do They Have a Therapeutic Window?
Background: In psychopharmacology, therapeutic window is the drug concentration range that ensures safe and effective outcomes, with a higher risk of treatment failure outside this range. Dopamine receptor partial agonists (DRPAs) illustrate this concept, particularly in treating depression, as they require specific doses to balance efficacy and safety. Methods: PubMed search focused on randomized controlled trials, open-label studies, and reviews evaluating aripiprazole, brexpiprazole, and cariprazine as augmentation therapies for major depressive disorder in adults. Results: Clinical trials on aripiprazole, brexpiprazole, and cariprazine as antidepressant adjuncts show that effective doses are typically lower than antipsychotic doses: 2-10 mg for aripiprazole (vs 10-30 mg), 2-3 mg for brexpiprazole (vs 4 mg), and 1.5-3 mg for cariprazine (vs 1.5-4.5 mg). At subantipsychotic doses, partial agonists increase dopamine signaling, while at antipsychotic doses they reduce it to the drug’s intrinsic activity level (generally 25%-40% of maximal dopamine signal) which is generally inadequate for an antidepressant response. Conclusion: DRPAs modulate the dopamine signaling depending on receptor occupancy: higher occupancy reduces signaling, while lower occupancy (when unoccupied receptors can interact with endogenous dopamine) enhances it. Understanding the drug-receptor relationship is crucial, since higher doses are not always more effective.
- 25 June 2025
- Published by SAGE Publications in Annals of Clinical Psychiatry
- Vol. 36 (3) , 80-88
When an Antipsychotic Working as an Antidepressant, Do They Have a Therapeutic Window?
Background: In psychopharmacology, therapeutic window is the drug concentration range that ensures safe and effective outcomes, with a higher risk of treatment failure outside this range. Dopamine receptor partial agonists (DRPAs) illustrate this concept, particularly in treating depression, as they require specific doses to balance efficacy and safety. Methods: PubMed search focused on randomized controlled trials, open-label studies, and reviews evaluating aripiprazole, brexpiprazole, and cariprazine as augmentation therapies for major depressive disorder in adults. Results: Clinical trials on aripiprazole, brexpiprazole, and cariprazine as antidepressant adjuncts show that effective doses are typically lower than antipsychotic doses: 2-10 mg for aripiprazole (vs 10-30 mg), 2-3 mg for brexpiprazole (vs 4 mg), and 1.5-3 mg for cariprazine (vs 1.5-4.5 mg). At subantipsychotic doses, partial agonists increase dopamine signaling, while at antipsychotic doses they reduce it to the drug’s intrinsic activity level (generally 25%-40% of maximal dopamine signal) which is generally inadequate for an antidepressant response. Conclusion: DRPAs modulate the dopamine signaling depending on receptor occupancy: higher occupancy reduces signaling, while lower occupancy (when unoccupied receptors can interact with endogenous dopamine) enhances it. Understanding the drug-receptor relationship is crucial, since higher doses are not always more effective.
- 1 September 2024
- Published by Wiley in Bipolar Disorders
- Vol. 26 (8) , 772-778
Concept article: Antidepressant‐induced destabilization in bipolar illness mediated by serotonin 3 receptor (5HT3)
Objectives: Antidepressants used by patients with bipolar disorder have been associated with destabilization with an increase in mania, depression, and cycling. The most commonly proposed mechanism, that antidepressants ‘overshoot’ their antidepressant effect to create a manic or mixed state, is unlikely since antidepressants have actually been found to be ineffective in treating bipolar depression. Beginning with known bipolar‐specific pathophysiologic abnormalities provides the greatest likelihood of insight.Methods: PubMed was queried with ‘bipolar’, ‘sodium’, ‘intracellular sodium’, ‘serotonin 3’, ‘5HT3’, ‘5‐hydroxytryptamine type 3 receptors’, and ‘antidepressant’ either individually or in combination.Results: Pathologic mood states (both mania and depression) are associated with increased intracellular sodium (Na) concentrations that depolarize the resting membrane potential to increase cellular excitability (mania) or cause depolarization block (depression). Stimulation of the serotonin (5HT) receptors depolarizes the post‐synaptic neuron. Stimulation of 5HT3 may be of particular importance since it is coupled to a cation channel that directly depolarizes the membrane. These effects directly impact the physiology of patients with bipolar disorder to alter neuronal excitability in a fashion that worsens both mania and depression.Proposed Concept: The most consistently observed biological abnormality in individuals going through mania or bipolar depression involves a decline in Na pump activity, with consequent elevation of intracellular Na levels. Antidepressant treatment potentiates this, particularly by activation of 5HT3. This hypothesis can be tested by coadministering a 5HT3 antagonist (e.g., vortioxetine or ondansetron) to achieve blockade of that receptor while treating bipolar depression with a serotoninergic antidepressant.
- 1 September 2024
- Published by Wiley in Bipolar Disorders
- Vol. 26 (8) , 772-778
Concept article: Antidepressant‐induced destabilization in bipolar illness mediated by serotonin 3 receptor (5HT3)
Objectives: Antidepressants used by patients with bipolar disorder have been associated with destabilization with an increase in mania, depression, and cycling. The most commonly proposed mechanism, that antidepressants ‘overshoot’ their antidepressant effect to create a manic or mixed state, is unlikely since antidepressants have actually been found to be ineffective in treating bipolar depression. Beginning with known bipolar‐specific pathophysiologic abnormalities provides the greatest likelihood of insight.Methods: PubMed was queried with ‘bipolar’, ‘sodium’, ‘intracellular sodium’, ‘serotonin 3’, ‘5HT3’, ‘5‐hydroxytryptamine type 3 receptors’, and ‘antidepressant’ either individually or in combination.Results: Pathologic mood states (both mania and depression) are associated with increased intracellular sodium (Na) concentrations that depolarize the resting membrane potential to increase cellular excitability (mania) or cause depolarization block (depression). Stimulation of the serotonin (5HT) receptors depolarizes the post‐synaptic neuron. Stimulation of 5HT3 may be of particular importance since it is coupled to a cation channel that directly depolarizes the membrane. These effects directly impact the physiology of patients with bipolar disorder to alter neuronal excitability in a fashion that worsens both mania and depression.Proposed Concept: The most consistently observed biological abnormality in individuals going through mania or bipolar depression involves a decline in Na pump activity, with consequent elevation of intracellular Na levels. Antidepressant treatment potentiates this, particularly by activation of 5HT3. This hypothesis can be tested by coadministering a 5HT3 antagonist (e.g., vortioxetine or ondansetron) to achieve blockade of that receptor while treating bipolar depression with a serotoninergic antidepressant.
- 14 May 2024
- Published by Wiley in Bipolar Disorders
- Vol. 26 (8) , 827-830
Does serotonin reuptake inhibition provoke catatonia in patients with bipolar illness?
- 14 May 2024
- Published by Wiley in Bipolar Disorders
- Vol. 26 (8) , 827-830
Does serotonin reuptake inhibition provoke catatonia in patients with bipolar illness?
- Open Access
Immediate Effects of COVID-19 Outbreak on Psychiatric Outpatients: Posttraumatic Stress and Influencing Factors
We aimed to investigate the effects of COVID-19 outbreak and public health measures on the psychological well-being of patients with psychiatric disorders. This cross-sectional study assessed 436 outpatients recruited from a tertiary psychiatry clinic in Istanbul, Turkey, nearly one month after the government introduced strict measures of lockdown against the ongoing outbreak. Respondents completed a web-based survey on sociodemographic data, subjective sleep quality, and a range of psychiatric symptoms using the Impact of Events Scale-Revised (IES-R), and Hospital Anxiety and Depression Scale (HADS). Respondents reported high frequencies of clinically significant posttraumatic stress disorder (PTSD) (32.6%, IES-R score ≥ 33), anxiety (36.4%, HADS anxiety score > 10), and depression (51%, HADS depression score > 10). 20.5% of respondents described that their psychological status worsened during the COVID-19 outbreak, and 12.1% of respondents described poor or very poor sleep in the prior month. Positive predictors of increased PTSD symptoms included the chronic medical diseases, knowing someone in the social vicinity diagnosed with the COVID-19 infection, job loss or being on temporary leave after the outbreak, and increased exposure time to TV or social media. In contrast, male gender, older age, higher educational attainment, and the psychiatric diagnoses of schizophrenia and (to a lesser degree) bipolar disorder were the negative predictors. Our results suggest that patients with psychiatric disorders are prone to substantial psychological distress during the COVID-19 outbreak, and various individual, behavioral, and social factors mediate this effect.
Open AccessImmediate Effects of COVID-19 Outbreak on Psychiatric Outpatients: Posttraumatic Stress and Influencing Factors
We aimed to investigate the effects of COVID-19 outbreak and public health measures on the psychological well-being of patients with psychiatric disorders. This cross-sectional study assessed 436 outpatients recruited from a tertiary psychiatry clinic in Istanbul, Turkey, nearly one month after the government introduced strict measures of lockdown against the ongoing outbreak. Respondents completed a web-based survey on sociodemographic data, subjective sleep quality, and a range of psychiatric symptoms using the Impact of Events Scale-Revised (IES-R), and Hospital Anxiety and Depression Scale (HADS). Respondents reported high frequencies of clinically significant posttraumatic stress disorder (PTSD) (32.6%, IES-R score ≥ 33), anxiety (36.4%, HADS anxiety score > 10), and depression (51%, HADS depression score > 10). 20.5% of respondents described that their psychological status worsened during the COVID-19 outbreak, and 12.1% of respondents described poor or very poor sleep in the prior month. Positive predictors of increased PTSD symptoms included the chronic medical diseases, knowing someone in the social vicinity diagnosed with the COVID-19 infection, job loss or being on temporary leave after the outbreak, and increased exposure time to TV or social media. In contrast, male gender, older age, higher educational attainment, and the psychiatric diagnoses of schizophrenia and (to a lesser degree) bipolar disorder were the negative predictors. Our results suggest that patients with psychiatric disorders are prone to substantial psychological distress during the COVID-19 outbreak, and various individual, behavioral, and social factors mediate this effect.